A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

1. Males and females at least 18 years old at screening 2. Females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control 3. Chronic hepatitis C, genotype 1 infection 4. Males must be surgically sterile or agree to practice acceptable forms of birth control 5. Screening laboratory result indicating HCV genotype 1 infection

1. Use of contraindicated medications within 2 weeks of dosing 2. Abnormal laboratory tests 3. Current or past clinical evidence of Child-Pugh B or C classification or history of liver decompensation 4. Confirmed presence of hepatocellular carcinoma 5. History of solid organ transplant